Saturday 17 October 2026
Export TRVN’s income statement to Excel — free account
Trevena, Inc.
TRVN Healthcare Biotechnology
Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.07
−100.00%
Follow TRVN
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.84 | 10.09 | 2.71 | 3.01 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.71) | (0.62) | (0.90) | (1.57) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
40.88 | 46.52 | 6.82 | 2.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.82) | (0.65) | (0.68) | (0.25) | |
EV/FCF |
(0.82) | (0.65) | (0.68) | (0.25) | |
Quick Ratio |
2.26 | 3.14 | 3.27 | 4.37 | |
Current Ratio |
2.42 | 3.46 | 3.60 | 4.66 | |
Net Debt/EBITDA |
(3.49) | (2.36) | (1.22) | 0.22 | |
Debt/Assets |
171.33% | 137.41% | 113.92% | 75.87% | |
Debt/Equity |
(1.41) | (1.66) | (2.42) | (4.02) | |
Asset Turnover |
0.02 | 0.01 | 0.09 | 0.07 | |
Operating CF/Net income |
0.91 | 1.47 | 1.23 | 0.36 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.25) | |
Interest Coverage |
(5,577.00) | (12.48) | (19.26) | (5.44) | |
Research and Development Expense of Revenue |
659.36% | 962.15% | 19,825.00% | (5,089.02%) | |
Selling, General and Administrative Expense of Revenue |
1,371.02% | 1,107.08% | 29,225.00% | (5,623.17%) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
196.47% | 180.92% | 3,405.00% | (893.90%) | |
Graham Net Nets |
(8.70) | (5.34) | (2.33) | (1.39) | |
Graham Number |
170.06 | 166.62 | 161.01 | 162.68 | |
Earnings Yield |
(1,257.75%) | (1,059.16%) | (670.00%) | (423.43%) | |
Free Cash Flow Yield |
(850.47%) | (706.22%) | (371.11%) | (351.36%) | |
Revenue per Share |
0.33 | 0.38 | 0.02 | (0.16) | |
Operating CF per Share |
(5.28) | (8.42) | (11.05) | (11.75) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.04) | |
Free Cash Flow per Share |
(5.28) | (8.42) | (11.05) | (11.79) | |
Cash per Share |
16.11 | 19.19 | 27.64 | 64.73 | |
Shareholders Equity per Share |
(27.33) | (22.23) | (17.20) | (15.03) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(27.33) | (22.23) | (17.20) | (15.03) | |
Free Cash Flow |
(4.50) | (7.18) | (9.42) | (6.01) | |
Working Capital |
8.65 | 12.83 | 18.77 | 27.65 | |
Capital Expenditures |
— | — | — | (0.02) | |
Net Current Asset Value |
(27.76) | (23.87) | (19.81) | (13.06) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | (0.26) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.23 | 1.83 | 2.00 | 2.34 | |
Average Assets |
32.16 | 30.90 | 34.71 | 44.64 | |
Average Common Equity |
(9.88) | (4.59) | (2.25) | 3.97 |
Columns are period end dates